Full reference for bremelanotide (Vyleesi) — central mechanism, FDA trial data, dosing protocol, blood pressure considerations, and current COA-verified vendor pricing.
Research context only. PT-141 is FDA-approved as Vyleesi for HSDD in premenopausal women. All other use is off-label. Not medical advice.
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist developed from Melanotan II. It was granted FDA approval in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first FDA-approved treatment for HSDD that works centrally rather than through vascular mechanisms.
The distinction between central and peripheral mechanisms is the most important thing to understand about PT-141. PDE5 inhibitors (Viagra, Cialis) work by preventing the breakdown of cGMP in penile smooth muscle, increasing blood flow. They require sexual stimulation to work and depend on adequate vascular function.
PT-141 activates MC3R and MC4R in the hypothalamus, triggering dopaminergic pathways that increase sexual motivation and desire directly. It doesn't require vascular health to work — it generates desire at the neurological level. This is why it's effective for people who don't respond to vascular approaches and why it works in women (who don't benefit from increased penile blood flow).
Clinical implication: For psychogenic sexual dysfunction — where the issue is desire or arousal rather than physical vascular function — PT-141 addresses the root cause. For purely vascular erectile dysfunction, a PDE5 inhibitor remains more targeted. Many researchers use both: PT-141 for desire, PDE5 inhibitor for vascular support.
Two pivotal Phase 3 trials (RECONNECT) enrolled approximately 1,200 premenopausal women with HSDD. The trials used the Female Sexual Function Index (FSFI) and Female Sexual Distress Scale (FSDS-R) as primary endpoints.
| Endpoint | PT-141 1.75mg | Placebo |
|---|---|---|
| Satisfying sexual events / month | +1.2 vs baseline | +0.7 vs baseline |
| Sexual distress score | Significant reduction | Modest reduction |
| Nausea (most common AE) | ~40% | ~1% |
| Flushing | ~20% | ~2% |
| Serious adverse events | Rare | Rare |
The efficacy numbers are modest in absolute terms — an improvement of about one additional satisfying sexual event per month. The FDA's rationale for approval included both the statistical significance and the lack of alternatives addressing the central (desire) component of HSDD.
| Parameter | Value | Notes |
|---|---|---|
| Starting dose | 1mg | Recommended for first use to assess nausea tolerance |
| Standard dose | 1.75mg | FDA-approved clinical dose for Vyleesi |
| Timing | 45–90 min before | Allow 1–2 hours for full onset |
| Frequency | As needed | Maximum once per 72 hours per FDA label |
| Nausea mitigation | Light meal + start at 1mg | Most effective approach per trial data |
COA-verified vendor pricing with promo codes, reconstitution guide, and dosing protocol.
View Pricing → Dosage Calculator